Currently, MEK inhibitors are in clinical trials for several cancers, including colorectal cancer (CRC), specifically those with mutations in RAS or its downstream signaling component BRAF, which occur in several types of cancers4,5. The gene discussed is BRAF; the disease is colorectal carcinoma.